×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Nabriva Therapeutics (NASDAQ:NBRV) Research Coverage Started at StockNews.com
Defense World
Read Nabriva Therapeutics (NASDAQ:NBRV) Research Coverage Started at StockNews.com at Defense World.
5 days ago
The World Needs New Antibiotics. The Problem Is, No One Can Make Them Profitably.
WSJ
New drugs to defeat 'superbug' bacteria aren't reaching patients.
7 months ago
UPDATED: The 2023 Biotech Graveyard
Fierce Biotech
It's the time of year when the Fierce Biotech team sticks its shovel into fresh soil to bury another year's worth of biotechs.
6 months ago
Nabriva Therapeutics Provides Corporate Update
Yahoo Finance
Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset...
16 months ago
Antibiotic developer Nabriva to wind down
Chemical & Engineering News
Nabriva Therapeutics says it is going to wind down, becoming the latest antibiotic developer to fail commercially. Nabriva was formed in...
16 months ago
Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic
Labiotech.eu
The FDA has approved Nabriva Therapeutics' Xenleta for treating community-acquired bacterial pneumonia, the first in a new class of...
23 months ago
Nabriva Acquires Zavante Therapeutics and its Late-Stage Antibiotic
BioSpace
Shares of Nabriva Therapeutics are rising this morning after the company announced it acquired privately-held Zavante Therapeutics.
69 months ago
Nabriva hit with another FDA setback with complete response letter for antibiotic Contepo
Fierce Pharma
Nabriva Therapeutics threaded the needle from biotech to pharma after it notched its first FDA approval for antibiotic Xenleta back in...
47 months ago
Nabriva Therapeutics snaps up Zavante for its market-ready antibiotic
Pharmaceutical Technology
Nabriva made the strategic acquisition of privately held Zavante Therapeutics and its market-ready pipeline antibiotic drug in a deal of...
70 months ago
Complicated Urinary Tract Infection (cUTI) Market to Witness Growth by 2032, Estimates DelveInsight| Meiji Seika ...
FinancialContent
Complicated Urinary Tract Infection (cUTI) Market to Witness Growth by 2032, Estimates DelveInsight| Meiji Seika Pharma, Pfizer, Novartis,...
11 months ago